Publication details
Pembrolizumab v terapii výrazně předléčeného pacienta s ORL nádorem
| Title in English | Pembrolizumab in the treatment of a severely pre-treated patient with ENT cancer |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| web | http://www.actamedicinae.cz/literatura/AM_042020_literatura.pdf |
| Keywords | squamous cell carcinoma; chemotherapy; radiotherapy; predictive marker; pembrolizumab |
| Description | The case report describes the case of a 49-year-old patient with infiltration of the right orbit by low-differentiation squamous cell carcinoma. The patient underwent resection followed by adjuvant treatment. However, there was an early recurrence and further surgery, radiotherapy and systemic treatment were indicated. However, further disease progression precluded any curative intent. Because the patient was immunohistochemically PD-L1 positive in 70% and the chemotherapy options were exhausted, we asked the review physician to approve reimbursement of the anti-PD-1 antibody pembrolizumab. The response to the given immunotherapy could be observed relatively early and was significant, which was confirmed by subsequent PET / MR examination. There are several predictive factors for the effectiveness of immunotherapy, but the ideal is still lacking. |